From Disease Proteomics to Biomarker Development-Establishment of Antibody Proteomics Technology and Exploration of Cancer-related Biomarkers-

DOI Web Site Web Site 1 Citations 13 References
  • NAGANO Kazuya
    Laboratory of Pharmaceutical Proteomics (LPP), National Institute of Biomedical Innovation (NiBio)
  • IMAI Sunao
    Laboratory of Pharmaceutical Proteomics (LPP), National Institute of Biomedical Innovation (NiBio)
  • NAKAGAWA Shinsaku
    Graduate School of Pharmaceutical Sciences, Osaka University The Center for Advanced Medical Engineering and Informatics, Osaka University
  • TSUNODA Shin-ichi
    Laboratory of Pharmaceutical Proteomics (LPP), National Institute of Biomedical Innovation (NiBio) Graduate School of Pharmaceutical Sciences, Osaka University The Center for Advanced Medical Engineering and Informatics, Osaka University
  • TSUTSUMI Yasuo
    Laboratory of Pharmaceutical Proteomics (LPP), National Institute of Biomedical Innovation (NiBio) Graduate School of Pharmaceutical Sciences, Osaka University The Center for Advanced Medical Engineering and Informatics, Osaka University

Bibliographic Information

Other Title
  • 疾患プロテオミクスからバイオマーカーの創出へ―抗体プロテオミクス技術の確立とがん関連マーカーの探索―
  • シッカン プロテオミクス カラ バイオマーカー ノ ソウシュツ エ コウタイ プロテオミクス ギジュツ ノ カクリツ ト ガン カンレン マーカー ノ タンサク

Search this article

Abstract

  Molecular biomarkers are keys to the development of new diagnostic protocols and therapies. Recently, significant research effort has been devoted to the development of these biomarkers using various approaches. Perhaps the most promising approach is disease proteomics. This method involves analyzing and identifying changes in the expression pattern at the protein level in the diseased condition (disease-related proteins) by using two-dimensional differential gel electrophoresis analysis (2D-DIGE). In the case of disease proteomics, hundreds of candidate disease-related proteins can be identified at a time. Therefore, how to pick the really valuable proteins up from a number of candidate drug targets is the most important issue to be solved worldwide. Here, we introduce a novel approach, termed “antibody proteomics”, which addresses this issue. Using antibody proteomics it is possible to identify a variety of disease-related proteins by 2D-DIGE and simultaneously prepare monoclonal antibodies to these proteins by using a phage antibody library. The advantage of this technology is that the target proteins are identified in a high-throughput manner. Our approach relies on the fact that tissue microarray analysis can evaluate the relationship between disease-related proteins and disease progression, based on clinical and pathological information. In this review, we discussed the development and application of antibody proteomics and gave an overview of future work.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 130 (4), 487-492, 2010

    The Pharmaceutical Society of Japan

Citations (1)*help

See more

References(13)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top